3 completed. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 2 |
| Phase 2 | 1 | Completed 1 |
Follow Aptarion Biotech AG: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy of AON-D21 in Severe Community-Acquired Pneumonia. AON-D21, Placebo - Community-acquired Pneumonia | Phase 2 | Completed | Aptarion Biotech AG | 150 | 2024-02-02 | 2026-03-18 |
| Ascending Multiple Intravenous Doses of AON-D21 in Healthy Male Subjects. AON-D21, Placebo - Healthy | Phase 1 | Completed | Aptarion Biotech AG | 16 | 2022-04-12 | 2022-12-19 |
| First-in-human Trial With Single-dose C5a-neutralizing AON-D21 in Healthy Male Subjects Intravenous AON-D21, Intravenous placebo - Healthy | Phase 1 | Completed | Aptarion Biotech AG | 40 | 2021-08-03 | 2022-01-12 |
Community-Acquired Pneumonia (1) · Lymphoma, Follicular (1) · Pneumonia (1)
Germany (3) · Belgium (1) · France (1) · Spain (1) · United Kingdom (1) · United States (1)
Manuela Koch, MD (2) · Martin Witzenrath, MD (1)